Pharvaris N.V. (PHVS) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xencor (XNCR) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 109.6% versus a gain of 26.0%. Over five years, PHVS leads with a +131.3% price change compared with -6.2% for XNCR. Xencor is the larger company by market cap ($2.50 billion vs $2.21 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | XNCR |
|---|---|---|
| Share price | $31.28 | $33.26 |
| Market cap | $2.21B | $2.50B |
| 1-day change | -1.20% | -2.21% |
| YTD return | +12.72% | +117.24% |
| 1-year return | +25.98% | +109.58% |
| 5-year return | +131.28% | -6.15% |
| EPS (TTM) | $-3.13 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $125.58M |
| Revenue growth (YoY) | — | +13.65% |
| Net income (latest FY) | $-25.99M | $-91.92M |
| Operating margin | — | -141.35% |
| Net margin | — | -73.20% |
| 52-week high | $43.25 | $40.60 |
| 52-week low | $23.15 | $10.38 |
| Distance from 52-week high | -27.68% | -18.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +86.29% | +27.78% |
| Average volume | 756.20K | 1.54M |
| Shares outstanding | 70.79M | 75.04M |
| Employees | 168 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed PHVS by 83.6 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
PHVS vs XNCR FAQ
Which is bigger, Pharvaris N.V. or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.21B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, PHVS or XNCR?
XNCR returned +109.58% over the past 12 months, compared with +25.98% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.